Medacta Group SA · SIX:MOVE

Medacta Group SA — H1 2019 Earnings Presentation

25 slides from Medacta Group SA's earnings presentation, Sep 3, 2019

  1. Slide 1: 1H 2019 Financial results

    1H 2019 Financial results 3rd September 2019 PATIENT WELL-BEING MEDICAL EDUCATION INNOVATION 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the Medacta Half Year 2019 Report ava

  3. Slide 3: Agenda

    Agenda ▪ Business update ▪ 1H 2019 results ▪ Outlook 3

  4. Slide 4: Medacta expands further achieving strong revenue growth and profitability

    Medacta expands further achieving strong revenue growth and profitability Sales growth in all regions and business lines ▪ Revenues up by 13.8% to €151.6 million (+11.0% in CC1) ▪ Growth significantly above the market ▪ Adjusted and Normalized EBITDA margin of 31.0% (2) ▪ Substantial progress in the

  5. Slide 5: Business update

    Adedacta International Business update

  6. Slide 6: An international high-growth platform with a new approach to orthopedics

    An international high-growth platform with a new approach to orthopedics 1 2 3 4 5 High-growth Differentiated Dedicated Rich pipeline of Experienced and orthopedics company minimally invasive surgeon education innovation-led committed leadership with and personalized program offerings team internati

  7. Slide 7: Sales growth in all regions and business lines

    Sales growth in all regions and business lines: Revenues up by 13.8% to €151.6 million (+11.0% in CC) Growth by regions (%)1 Growth by products (%)1 Commentary ▪ Recorded strong organic growth in the first half of 2019 and Medacta sales increased by 13.8% compared to the RoW 18.2% Spine 11.1% same p

  8. Slide 8: Regional segments 1H 2019 vs 1H 2018

    Regional segments 1H 2019 vs 1H 2018 Revenue by regions (€m)1 Commentary Growth % ▪ In Europe, the largest region in terms of revenue, sales increased by 8.2% to 147.9 +18.2% €70.0 million, in line with last year’s 5.4 133.3 growth 4.6 30.2 +7.6% ▪ The growth in the US was particularly 28.1 high des

  9. Slide 9: Business segments 1H 2019 vs 1H 2018

    Business segments 1H 2019 vs 1H 2018 Revenue by products (€m)1 Commentary Growth % ▪ Revenue growth above market averages across all business lines 147.9 +11.1% ▪ In Hip, the AMIS approach continued to 133.3 10.5 4.0 +171.3% drive growth due to better operating 9.5 1.5 room efficiency, better accura

  10. Slide 10: Impactful Lugano Congress highlights Medacta's innovation leadership

    Impactful Lugano Congress highlights Medacta’s innovation leadership 9th M.O.R.E. international symposium ▪ Focus on the growing trend of personalized medicine and the impact of customizable tools and patient-matched solutions in various orthopedic disciplines ▪ 1,500 attendees, 900 orthopedic surge

  11. Slide 11: MySpine MIS Midline Cortical Platform awarded Best Healthcare Navigation / Robotics Solution

    MySpine MIS Midline Cortical (MC) Platform awarded Best Healthcare Navigation / Robotics Solution Next generation healthcare navigation and robotics solution ▪ MedTech Breakthrough Awards recognize game-changing technologies throughout the medical industry ▪ MySpine MIS1 MC is a minimally invasive,

  12. Slide 12: Sustained growth of the shoulder business underlined by the launch of new products

    Sustained growth of the shoulder business underlined by the launch of new products Medacta Shoulder System: An innovative modular shoulder replacement system ▪ Successfully rolled out the Medacta Shoulder System in the US, Australia and Japan ▪ Continued introduction of key technologies across globa

  13. Slide 13: 1H 2019 Financial performance

    1H 2019 Financial performance 13

  14. Slide 14: Key figures 1H 2019

    Key figures 1H 2019 Adjusted and Norm.(1) Revenue (€m) Gross profit (€m) EBITDA (€m) 151.6 111.6 47.0 Adjusted and Norm. (1) Adjusted and Norm. (1) Revenue growth EBITDA growth EBITDA margin +13.8% +8.8% 31.0% +11.0% cc Notes: 1. For a reconciliation to Reported EBITDA, see page 17 of this presentat

  15. Slide 15: Gross profit 1H 2019 vs 1H 2018

    Gross profit 1H 2019 vs 1H 2018 Reported Revenue vs. gross profit (€m) Commentary ▪ Strong levels of profitability 151.6 ▪ Variation between periods are normal due to phasing of some industrial costs 133.3 ▪ 1H 2019 reduction driven by: 40.1 o Expected price reductions occurring 33.6 in the second s

  16. Slide 16: Operating expenses 1H 2019 vs 1H 2018

    Operating expenses 1H 2019 vs 1H 2018 Operating expenses bridge (€m) Commentary % of 62.2% 52.3% 51.9% revenue ▪ Non-recurring expenses of €14.9m: 94.3 o Other Net Expenses/Income include one- 5.2 time stamp duty costs of €5.7m related to 3.5 (14.9) 79.4 the change of ownership structure 2.3% 3.5 o

  17. Slide 17: Adjusted and Normalized EBITDA margin of 31.0%

    Adjusted and Normalized EBITDA margin of 31.0% (4) EBITDA bridge (€m) Commentary % of 22.1% 31.0% 32.4% revenue ▪ Adjusted and Normal. EBITDA of €47.0m, corresponding to a margin of 31.0% on 4.9 revenue compared to 32.4% in 1H 2018 (1.4 ) 47.0 ▪ For the Lugano 9th M.O.R.E. Symposium in 5.7 43.2 Apri

  18. Slide 18: 1H 2019 Results - Capital expenditures

    1H 2019 Results - Capital expenditures Investments in tangible and intangible assets Commentary (€m) % of 19.3% 25.6% 17.0% revenue 1H 2019: 52.7 • Capex less than 1H 2018 (€8.3m) 2.0 mainly due to: Intangibles 7.9 10.0 o Land & Building, (€15.0m), for new plant in Rancate bought in 2018 1.7 o Instr

  19. Slide 19: 1H 2019 Results – Adjusted and Normalized Cash flow and working capital

    1H 2019 Results – Adjusted and Normalized Cash flow (4) and working capital Consolidated cash flow Commentary (€m) 1H 2019 1H 2018 • Reduction in adjusted free cash flow Cash flow from operating activities 14.8 31.2 due to higher investments in instruments in 1H 2019 along with an increase in Cash f

  20. Slide 20: Outlook

    Adedacta International Outlook

  21. Slide 21: Priorities 2H 2019

    Priorities 2H 2019 ▪ Follow-up on the M.O.R.E. activities of 1H to have a notable impact on 2H sales ▪ Expansion of core joint products in key markets ▪ Increase market penetration in key geographies and innovation in product portfolio to accelerate growth in the knee segment ▪ Continue to drive spi

  22. Slide 22: Outlook: Financial Targets

    Outlook: Financial Targets Metric 2019 Target Commentary Revenue growth Mid teens On track / low-end Adjusted EBITDA margin1 32% +/- 100bps On track / low-end Capex ~10-12% of total revenue Above target Change in Net Working Capital ~5-7% of total revenue On track Tax rate ~21% Better than target Di

  23. Slide 23: Key Pillars of Medacta's Growth Strategy

    Key Pillars of Medacta’s Growth Strategy Growth of New Product Segments and Continued Technologies Innovation in Established Increase Penetration in Hip and Knee Portfolio 3 Existing A Markets 2 Continued Expansion of Spine 1 Core hip and knee business grew by 9% B Successful Roll-out c.18% (CC) of

  24. Slide 24: Appendix

    Adedacta International Appendix

  25. Slide 25: Consolidated financial statements (unaudited)

    Consolidated financial statements (unaudited) Profit & loss statement (€m) (€'000) 1H 2019 1H 2018 Revenues 151,638 133,271 Growth (%) 13.8% COGS (40,059) (33,588) Gross profit 111,579 99,683 Margin (%) 73.6% 74.8% R&D expenses (3,502) (2,231) Sales and Marketing expenses (61,566) (51,235) General a

Medacta Group — H1 2019 Earnings Presentation on 6ix